Monitor future quarterly filings for any revenue contribution from the IM8 segment, particularly in Asia-Pacific markets. The NBA partnership provides brand credibility but lacks disclosed financial commitments — watch for concrete sales data or expansion announcements in subsequent 10-Q/6-K filings.
Price Chart
Executive Summary
Prenetics Global Ltd announced a multi-year collaboration with the NBA making its IM8 brand the Official Nutrition Partner of the NBA in Australia and eight Southeast Asian markets. The partnership includes NBA-themed marketing campaigns and a fan activation at NBA House in 2027, targeting approximately 660 million people in the region. This is a brand-building agreement with no disclosed financial terms, representing a positive but non-material commercial development for the IM8 subsidiary.
Key Facts
- Multi-year collaboration with the NBA announced October 12, 2026
- IM8 named Official Nutrition Partner of the NBA in Australia and 8 Southeast Asian markets (Brunei, Cambodia, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam)
- IM8 will host a fan activation at NBA House in the region in 2027
- Partnership targets approximately 660 million people across Australia and Southeast Asia
- IM8 is a wholly owned subsidiary of Prenetics Global Limited (NASDAQ: PRE)
- IM8 co-founded by David Beckham and Danny Yeung; athlete ambassadors include Giannis Antetokounmpo
- IM8 launched in December 2024, ships to 46 countries, has delivered more than 57 million servings
Financial Impact
No financial terms disclosed; brand partnership with NBA provides marketing exposure across 9 markets covering ~660M people
Risk Factors
- No financial terms disclosed — revenue impact uncertain
- IM8 is a recently launched brand (Dec 2024) with unproven scale in these markets
- Forward-looking statements caution that actual results may differ materially
- Partnership is regional (Australia + SE Asia), not global
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-065584 |
| Document: nbaxim8_final101226xvff.htm | 0001628280-26-065584 |
| Document: 0001628280-26-065584-index-headers.html | 0001628280-26-065584 |
| Document: 0001628280-26-065584-index.html | 0001628280-26-065584 |
| Document: 0001628280-26-065584.txt | 0001628280-26-065584 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $21.27 | awaiting T+60 | — | $18.37 (−13.63%) |
Sep 22, 2026 4w ago | F-1/A | $22.90 | awaiting T+60 | — | $18.37 (−19.78%) |
Aug 26, 2026 8w ago | 6-K | $25.78 | awaiting T+60 | — | $18.37 (−28.74%) |
Aug 26, 2026 8w ago | Insider Cluster | $25.78 | awaiting T+60 | — | $18.37 (−28.74%) |
Aug 26, 2026 8w ago | 3 | $25.78 | awaiting T+60 | — | $18.37 (−28.74%) |
Aug 20, 2026 9w ago | 6-K | $17.97 | awaiting T+60 | — | $18.37 (+2.23%) |
Aug 18, 2026 9w ago | 6-K | $19.40 | awaiting T+60 | — | $18.37 (−5.31%) |
Aug 18, 2026 9w ago | Press Release | $19.40 | awaiting T+60 | — | $18.37 (−5.31%) |
Aug 17, 2026 10w ago | 6-K | $19.37 | awaiting T+60 | — | $18.37 (−5.16%) |
Aug 7, 2026 11w ago | F-1/A | $18.26 | awaiting T+60 | — | $18.37 (+0.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers